# METHYLSCAPE-CO (Methylscape test in body fluids, Colombia)

Source: https://onco.cc/trials/methylscape-co/  
OnCo record `methylscape-co` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Colombian study of a rapid test that reads overall DNA methylation in blood, urine or saliva using gold nanoparticles.

## Summary

METHYLSCAPE-CO (NCT07741435) is an observational study sponsored by Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo. It evaluates the sensitivity and specificity of Methylscape, which uses the different binding of methylated and unmethylated DNA to gold nanoparticles to detect a cancer signal and predict its origin.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 3,250 participants, a start on 5 June 2025 and primary completion expected on 4 June 2027.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: METHYLSCAPE-CO
- Registry id: NCT07741435
- Phase: observational
- Setting: Patients with biopsy-confirmed solid tumours and controls in Colombia, testing blood, urine and saliva
- Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
- Enrolled: 3250

## Sources

- ClinicalTrials.gov NCT07741435: https://clinicaltrials.gov/study/NCT07741435

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/methylscape-co.json